Clinical Trials Logo
  1. Home
  2. Other
  3. NCT01004211

Prospective Randomized Comparison of Transurethral Resection by Mean of White Light and Narrow Band Imaging

Non Muscle Invasive Bladder Cancer Clinical Trial

Official title:
A Phase III Prospective Multicenter Randomized Comparison of Transurethral Resection by Mean of White Light and Narrow Band Imaging.

Clinical Trial Summary

To date, fluorescence and narrow band imaging cystoscopy have been tested in many prospective within patient trials but only as an "add on" procedure. This results in a bias that does not allow to determine the real impact of such innovative technologies on bladder cancer management. Hereby we propose the first prospective randomized trial which compares narrow band imaging trans urethral resection as a stand alone procedure versus white light transurethral resection. The primary end point is to assess the recurrence rate of bladder cancer lesions with each treatment modality. The study is designed to disclose an inferior recurrence rate (estimated 10%) in the group treated by narrow band imaging transurethral resection respect to the control group, treated by standard transurethral resection.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01004211
Study type Interventional
Source IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Contact
Status Completed
Phase N/A
Start date August 2009
Completion date October 2011
View Details
See also
  Status Clinical Trial Phase
Completed NCT06020807 - Analytical Specificity of Bladder EpiCheck Test in Healthy Population and Urology Patients Without Prior History or Evidence of Bladder Cancer
Recruiting NCT06167356 - Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK.
Withdrawn NCT01799499 - A Prospective Open Label Comparative Dose Ranging Study Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) N/A
Completed NCT02343614 - Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer Phase 2
Recruiting NCT05945108 - Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDER
Recruiting NCT06287541 - The Necessity of a Second Transurethral Resection in High-risk Non-muscle-invasive Bladder Cancer Patients With Negative Urine Biomarker After Initial Transurethral Resection N/A
Recruiting NCT06181266 - A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer Phase 1
Terminated NCT02982395 - Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC Phase 3
Completed NCT06205277 - Predictors of Residual Tumor at Second Transurethral Resection for pT1 Non-muscle Invasive Bladder Cancer
Completed NCT01731652 - Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer Phase 2
Recruiting NCT03421236 - Intravesical Ty21a for the Treatment of Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Phase 1
Active, not recruiting NCT04387461 - Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin Phase 2
Recruiting NCT06111235 - A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT Phase 3
Recruiting NCT02895620 - Effect on Xpert® Bladder Test of Urines Inflammatory Milieu Induced by BCG Treatment of Patients With NMIBC N/A
Active, not recruiting NCT05981131 - Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)